Skip to main content
AB Science logo

AB Science — Investor Relations & Filings

Ticker · AB ISIN · FR0010557264 LEI · 969500U43TVR8CCVBJ97 PA Manufacturing
Open in API
Filings indexed 742 across all filing types
Latest filing 2021-07-29 Earnings Release
Country FR France
Listing PA AB

About AB Science

https://www.ab-science.com

AB Science is a clinical-stage pharmaceutical company that researches, develops, and markets protein kinase inhibitors for human and veterinary medicine. The company focuses on developing innovative drugs for diseases with high unmet medical needs. Its pipeline is centered on two main compounds: masitinib and AB8939. Masitinib, a highly selective tyrosine kinase inhibitor, is under investigation for treating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's disease, as well as inflammatory diseases like mastocytosis. AB8939 is a microtubule destabilizer being developed for oncology, specifically for Acute Myeloid Leukemia (AML). The company also commercializes masitinib in veterinary medicine under the brand name Masivet®.

Recent filings

Filing Released Lang Actions
AB Science announced that results from its Phase 3 AB09004 study on mild to moderate Alzheimer’s disease have been presented at the AAIC
Earnings Release Classification · 1% confidence The document is explicitly titled "PRESS RELEASE" and announces the presentation of results from a clinical study (AB09004) at a major conference (AAIC). It provides key financial/clinical highlights, quotes from management, and details about the drug and the company. This format—an initial announcement of results or significant findings, often preceding a full report or transcript—aligns best with an Earnings Release (ER), which covers periodical financial/operational results, or potentially an Investor Presentation (IP) if it were structured as slides, but the press release format strongly suggests an ER or a general announcement. Given the content focuses on clinical trial results and their significance, which often accompanies or precedes quarterly financial reporting, 'ER' (Earnings Release) is the most appropriate classification for a press release detailing significant operational/clinical milestones that impact future performance. It is not a full 10-K, an Audit Report (AR), or a transcript (CT). Since it is a press release announcing results, ER is preferred over the more general RNS or the presentation-focused IP. FY 2021
2021-07-29 English
AB Science today announced that an abstract reporting results from its Phase 3 AB09004 study on Alzheimer’s disease has been selected for an oral presentation at the annual Alzheimer’s Association Int
Regulatory Filings Classification · 1% confidence The document is explicitly titled "PRESS RELEASE" and announces that AB Science will present results from a Phase III study at a major conference (AAIC 2021). It provides details about the presentation, including the title, date, and time, and includes standard company boilerplate and forward-looking statements. This is not a full financial report (10-K or IR), an earnings release (ER) which focuses on period results, or a presentation itself (IP). It is an announcement about an upcoming presentation of scientific/clinical data. Since it is a press release announcing a specific event and data presentation, it most closely aligns with a general Regulatory Filing (RNS) or potentially an Investor Presentation (IP) if it were the actual slides, but as a press release announcing the presentation, RNS is the most appropriate general category for non-standard announcements, or potentially a specialized category if one existed for clinical trial updates. Given the provided definitions, RNS (Regulatory Filings - general regulatory announcements and fallback) is the best fit for a clinical trial presentation announcement via press release, as it doesn't fit ER, CT, IP, or AR specifically.
2021-07-22 English
AB Science annonce qu’un résumé de son étude de phase 3 dans la maladie d’Alzheimer a été sélectionné pour une présentation orale à la Alzheimer’s Association International Conference (AAIC)
Regulatory Filings Classification · 1% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and announces that AB Science will present Phase 3 study results (AB09004 for Alzheimer's disease) at the AAIC 2021 conference. It details the presentation title, date, and time, and includes standard company information and forward-looking statements. This is not a full financial report (10-K or IR), an earnings release (ER) which focuses on financial figures, or a formal regulatory filing like a proxy statement. It is an announcement about upcoming scientific/clinical data presentation, which is best categorized as a general corporate announcement or a specific type of investor communication. Given the options, it is a communication aimed at investors/the public regarding company progress, but it is not a formal 'Investor Presentation' (IP) which usually contains slides/detailed strategy. Since it is a press release announcing scientific data presentation, and it doesn't fit the specific financial report codes, the most appropriate general category for a non-standard, non-financial regulatory announcement is 'Regulatory Filings' (RNS) as a fallback, or potentially 'Investor Presentation' (IP) if the announcement itself is considered the primary communication vehicle for the data summary. However, since it is explicitly a press release announcing a presentation, and not the presentation itself, RNS (Regulatory Filings/General Announcement) is the safest fallback, although it strongly relates to R&D progress. Given the context of financial reporting databases, announcements of clinical trial data presentations often fall under general news/regulatory updates. I will classify it as RNS as it is a general corporate communication/press release not covered by other specific codes.
2021-07-22 French
AB Science announces the publication of an article in the world-renowned journal Science that confirms potential of masitinib as a treatment of Covid-19 with anti-viral activity against SARS-CoV-2 and
Regulatory Filings Classification · 1% confidence The document is explicitly labeled as a "PRESS RELEASE" announcing the publication of research findings in the journal *Science* regarding the drug Masitinib's potential treatment for COVID-19. It details scientific results, quotes researchers, and mentions future clinical studies. This format—a formal announcement of significant company news, often related to R&D or clinical progress, distributed via press release—is characteristic of an Earnings Release (ER) if it were summarizing financial results, or more generally, a Regulatory Filing (RNS) if it doesn't fit a more specific category. Since this is a scientific/clinical development announcement, and not a formal financial report (like 10-K, IR, or ER), it best fits the general category for significant regulatory or corporate announcements that aren't strictly financial reporting or management changes. Given the options, 'Regulatory Filings' (RNS) serves as the best general category for non-standard, yet important, corporate disclosures like this press release about scientific validation.
2021-07-20 English
AB Science annonce la publication d’un article dans la revue de renommée mondiale Science qui confirme le potentiel du masitinib comme traitement de la Covid-19 avec une activité antivirale contre le
Regulatory Filings Classification · 1% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and announces the publication of research findings in the journal *Science* regarding the drug Masitinib's potential as a COVID-19 treatment. It details scientific results, quotes researchers, and mentions ongoing and planned clinical studies. This format—a formal announcement of significant company news, often related to research, clinical trials, or partnerships, released to the public and media—is characteristic of a general regulatory announcement or press release. Since it is not a full financial report (10-K, IR), a specific financial event (CAP, DIV), or a transcript (CT), and it is a formal communication of material information, it best fits the general regulatory announcement category, which is RNS (Regulatory Filings) as the fallback for non-specific corporate news releases, or potentially ER if it were focused purely on financial results, which it is not. Given the focus on scientific publication and development updates, RNS is the most appropriate general classification.
2021-07-20 French
AB Science announces the publication of new survival data showing that masitinib extended survival in ALS by 25 months relative to placebo
Regulatory Filings Classification · 1% confidence The document is explicitly titled "PRESS RELEASE" and announces the "PUBLICATION OF LONG-TERM FOLLOW-UP SURVIVAL DATA" in a peer-reviewed journal. It details clinical trial results (AB10015 and AB19001) regarding masitinib for ALS, including survival statistics and expert commentary. This format—a formal announcement of scientific/clinical findings outside of mandatory periodic financial reports (like 10-K or IR)—is characteristic of an Earnings Release (ER) if it were focused on financial results, or more generally, a Regulatory Filing (RNS) if it's a broad announcement of material, non-financial news. Since the content is a scientific/clinical update rather than a financial earnings summary, and it is a formal press release announcing a publication, it fits best under the general 'Regulatory Filings' (RNS) category, which serves as a catch-all for significant, non-standard announcements. It is not a full report (10-K, IR), a presentation (IP), or a management discussion (MDA). Given the nature of announcing clinical data publication, RNS is the most appropriate fit among the provided options for a general regulatory/material announcement.
2021-07-19 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.